NASDAQ$PLSE
Pulse Biosciences Inc · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
Pulse Biosciences reported financial results for Q4 2019.
Pulse Biosciences reported a net loss of $13.8 million for the fourth quarter ended December 31, 2019. The company's cash, cash equivalents, and investments totaled $25.4 million as of December 31, 2019. Operating expenses for the quarter were $13.9 million.
- Nano-Pulse Stimulation™ (NPS™) technology was highlighted in three clinical study presentations demonstrating its high clearance rates of benign skin lesions.
- Data was presented from a study evaluating the clinical and histologic response of NPS technology in treating challenging cases of nodular Basal Cell Carcinoma.
- Enrollment was completed in the Company’s CellFX Warts Pivotal Study.
- The company obtained ISO-13485:2016 Quality System Management Certification to begin preparations for international commercialization of the CellFX System.
Headline financials
Revenue & EPS history
Pulse Biosciences · Revenue · Quarterly
$0
Forward guidance
Pulse Biosciences is focused on obtaining FDA clearance for the CellFX System in aesthetic dermatology and is generating additional data to support a new 510(k) submission.
Tailwinds
- The company is focused on generating and providing additional data that will support a new 510(k) submission for what we believe will be a general dermatologic indication.
- Confidence in the technology continues to grow.
- FDA meeting is expected to take place in May.
- Developing innovative health products.
- The CellFX System is intended to offer customer value with a utilization-based revenue model across an expanding spectrum of clinical applications.
Headwinds
- The company received a Not Substantially Equivalent Letter from the U.S. Food and Drug Administration (FDA) on its previous 510(k) submission.
- The company remains engaged with the FDA to determine the regulatory path forward for the CellFX System.
- The company recently requested a formal Q-submission meeting with FDA to discuss requirements for a new 510(k) submission.
- The CellFX System and Nano-Pulse Stimulation (NPS) technology are for investigational use only.
- The company is pursuing a rights offering seeking to raise $30 million in net proceeds.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2019
-0.0%
Avg return
Earnings day
+1.2%
Avg return
5 days after
+9.3%
Avg return
30 days after
49%
19 / 39 earnings
Positive
+33.9%
Q4 2022
Best reaction
-36.5%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.6% | -4.6% | +34.5% | |
| Q4 2025 | -14.4% | -23.4% | -11.9% | |
| Q3 2025 | -1.2% | -6.1% | -20.0% | |
| Q1 2025 | +1.4% | -3.3% | +1.5% | |
| Q4 2024 | +6.0% | +6.8% | +14.4% | |
| Q3 2024 | +2.3% | -10.9% | +25.6% | |
| Q2 2024 | +8.1% | +21.5% | +9.5% | |
| Q1 2024 | -10.7% | -3.6% | +88.2% | |
| Q4 2023 | -4.9% | -8.5% | -14.4% | |
| Q3 2023 | +12.8% | +18.6% | +95.5% | |
| Q2 2023 | -0.4% | +9.2% | -35.3% | |
| Q1 2023 | -2.5% | -4.6% | -16.0% | |
| Q4 2022 | +33.9% | +57.4% | +156.6% | |
| Q3 2022 | +10.9% | +12.5% | +57.1% | |
| Q2 2022 | +8.7% | +10.6% | +1.2% | |
| Q1 2022 | -36.5% | -7.7% | -3.9% | |
| Q4 2021 | -28.4% | -25.0% | -49.6% | |
| Q3 2021 | -0.2% | -1.5% | -21.4% | |
| Q2 2021 | +7.9% | -2.1% | +2.1% | |
| Q1 2021 | +4.8% | +1.7% | +3.6% | |
| Q4 2020 | -9.2% | -17.5% | -35.1% | |
| Q3 2020 | +15.9% | +22.3% | +40.5% | |
| Q2 2020 | -6.4% | -6.1% | -15.0% | |
| Q1 2020 | +18.8% | -1.7% | -27.2% | |
| Q4 2019 | +21.1% | +5.2% | +14.6% | |
| Q3 2019 | -3.5% | -2.8% | -1.7% | |
| Q2 2019 | -2.5% | +4.6% | +16.1% | |
| Q1 2019 | -32.5% | -22.1% | -26.8% | |
| Q4 2018 | +4.0% | +11.3% | +9.4% | |
| Q3 2018 | +22.7% | +32.7% | +17.3% | |
| Q2 2018 | -0.9% | -6.7% | +4.1% | |
| Q1 2018 | -14.7% | -25.1% | -12.4% | |
| Q4 2017 | +0.1% | +1.8% | +38.5% | |
| Q3 2017 | +9.1% | +18.0% | -11.0% | |
| Q2 2017 | -16.6% | -11.6% | -25.2% | |
| Q1 2017 | -9.5% | -14.7% | +24.9% | |
| Q4 2016 | +6.4% | +18.7% | +12.7% | |
| Q3 2016 | +0.0% | -0.7% | -10.6% | |
| Q2 2016 | +1.5% | +2.2% | +31.3% | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro